AR083454A1 - Antigeno de citomegalovirus - Google Patents

Antigeno de citomegalovirus

Info

Publication number
AR083454A1
AR083454A1 ARP110103818A AR083454A1 AR 083454 A1 AR083454 A1 AR 083454A1 AR P110103818 A ARP110103818 A AR P110103818A AR 083454 A1 AR083454 A1 AR 083454A1
Authority
AR
Argentina
Prior art keywords
citomegalovirus
antigen
fusion loop
domain
loop domain
Prior art date
Application number
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR083454A1 publication Critical patent/AR083454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un polipéptido gB del citomegalovirus (CMV) que comprende al menos una porción de un dominio extracelular de la proteína gB que comprende un dominio de bucle de fusión 1 (FL1) y un dominio de bucle de fusión 2 (FL2), en la que al menos uno de los dominios FL1 y FL2 comprende al menos una deleción o sustitución de un aminoácido.Reivindicación 1: Un polipéptido gB del citomegalovirus (CMV) que comprende al menos una porción de un dominio extracelular de la proteína gB que comprende un dominio de bucle de fusión 1 (FL1) y un dominio de bucle de fusión 2 (FL2), en la que al menos uno de los dominios FL1 y FL2 comprende al menos una deleción o sustitución de un aminoácido.
ARP110103818 2010-10-15 2011-10-14 Antigeno de citomegalovirus AR083454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39341310P 2010-10-15 2010-10-15

Publications (1)

Publication Number Publication Date
AR083454A1 true AR083454A1 (es) 2013-02-27

Family

ID=44789497

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103818 AR083454A1 (es) 2010-10-15 2011-10-14 Antigeno de citomegalovirus

Country Status (20)

Country Link
US (1) US20130216613A1 (es)
EP (1) EP2627352B1 (es)
JP (1) JP6138047B2 (es)
KR (1) KR20130140009A (es)
CN (1) CN103237560B (es)
AR (1) AR083454A1 (es)
AU (1) AU2011315447A1 (es)
BR (1) BR112013008624B1 (es)
CA (1) CA2813522C (es)
CL (1) CL2013001037A1 (es)
CO (1) CO6741153A2 (es)
CR (1) CR20130191A (es)
DO (1) DOP2013000080A (es)
ES (1) ES2635014T3 (es)
IL (1) IL225667A0 (es)
MA (1) MA34802B1 (es)
MX (1) MX2013004149A (es)
SG (1) SG189176A1 (es)
TW (1) TW201305190A (es)
WO (1) WO2012049317A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2779459A1 (en) * 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
CN105980570B (zh) * 2013-12-03 2022-06-07 霍欧奇帕生物科技有限公司 Cmv疫苗
AU2014362234B2 (en) * 2013-12-11 2019-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3426676A1 (en) * 2016-03-11 2019-01-16 Pfizer Inc Human cytomegalovirus gb polypeptide
CN106119286A (zh) * 2016-08-10 2016-11-16 吴江近岸蛋白质科技有限公司 表达载体及其高效表达和制备人胱抑素c蛋白的方法
CA3057715A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2020085457A1 (ja) 2018-10-25 2020-04-30 Ｋｍバイオロジクス株式会社 改変ＣＭＶ ｇＢタンパク質及びこれを含むＣＭＶワクチン
US20220023416A1 (en) * 2018-12-10 2022-01-27 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
EP4161570A1 (en) 2020-06-05 2023-04-12 GlaxoSmithKline Biologicals S.A. Modified betacoronavirus spike proteins
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
US20230303637A1 (en) 2020-06-12 2023-09-28 Glaxosmithkline Biologicals Sa Gbs ferritin nanoparticles
TWI810589B (zh) * 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4237085A1 (en) 2020-10-28 2023-09-06 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CA3232004A1 (en) * 2021-09-16 2023-03-23 Rajiv KHANA "immunogenic compositions and uses thereof"
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
BR9408071A (pt) 1993-11-17 1996-12-24 Om Lab Sa Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
GB9409962D0 (en) 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
HUP0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
AU761396B2 (en) 1998-06-30 2003-06-05 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
CA2699756A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infection
WO2010089129A1 (en) * 2009-02-06 2010-08-12 Cormus Srl Inhibitors of viral fusion and uses thereof
CA2779459A1 (en) * 2009-10-30 2011-05-05 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
US20130196903A1 (en) * 2010-08-11 2013-08-01 Jv Bio Srl Multimeric Inhibitors of Viral Fusion and Uses Thereof

Also Published As

Publication number Publication date
BR112013008624B1 (pt) 2022-07-26
WO2012049317A3 (en) 2012-06-21
US20130216613A1 (en) 2013-08-22
AU2011315447A1 (en) 2013-05-09
JP2013544074A (ja) 2013-12-12
SG189176A1 (en) 2013-05-31
IL225667A0 (en) 2013-06-27
WO2012049317A2 (en) 2012-04-19
BR112013008624A2 (pt) 2021-05-11
CO6741153A2 (es) 2013-08-30
TW201305190A (zh) 2013-02-01
JP6138047B2 (ja) 2017-05-31
CL2013001037A1 (es) 2013-08-30
CN103237560A (zh) 2013-08-07
MA34802B1 (fr) 2014-01-02
EP2627352A2 (en) 2013-08-21
CA2813522A1 (en) 2012-04-19
MX2013004149A (es) 2013-09-02
KR20130140009A (ko) 2013-12-23
CN103237560B (zh) 2016-05-11
EP2627352B1 (en) 2017-05-10
ES2635014T3 (es) 2017-10-02
DOP2013000080A (es) 2013-08-15
CA2813522C (en) 2022-06-21
CR20130191A (es) 2013-06-28

Similar Documents

Publication Publication Date Title
AR083454A1 (es) Antigeno de citomegalovirus
CL2016000249A1 (es) Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
BR112014019901A2 (pt) proteínas de fator viii recombinante
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CO2017002166A2 (es) Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa
EA202090216A2 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
PE20171111A1 (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
MX2019011952A (es) Proteina anti-garp y sus usos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
MX2015005675A (es) Composiciones y metodos para modular la comunicacion celular.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201000077A1 (ru) Вирус гриппа с нарушенной репликацией для экспрессии гетерологичных последовательностей
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
NZ630854A (en) Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
CY1123654T1 (el) Αποδεσμευση πρωτεϊνης me βαση βακτηρια
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
DK1856159T3 (da) Kimære, rekombinante antigener af Toxoplasma gondii
EP2525816A4 (en) PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
TR201903573T4 (tr) Npp1 füzyon protei̇nleri̇.
MX2012013807A (es) Proteina de fusion que tiene actividad de factor vii.
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure